Browsing Category

Features

1035 posts

The EU and Fine Chemicals: Is Change Coming?
By

By
The European Commission’s Pharmaceutical Strategy for Europe calls for a structured dialogue to identify vulnerabilities in the pharma supply chain and provide policy options to strengthen medicines supply in the…

New Drug Approvals in 2020: Which Drugs Made the Mark?
By

By
In 2020, the FDA approved 53 new molecular entities (NMEs), the second highest level of NMEs approved in a given year in the past decade and over the 48 approvals…

Manufacturing and Supply Lines: New Ways for Risk Mitigation Post COVID-19
By

By
The COVID-19 pandemic has obliged a re-evaluation of manufacturing networks and supply lines. An upcoming DCAT webinar, Pharma’s Manufacturing and Supply Lines: New Ways for Risk Mitigation Post COVID-19, provides thought…

Pharma Outsourcing Outlook for 2021: The CDMO Industry Scales Up
By

By
The CDMO industry enters 2021 in the strongest position it has ever been in. The industry has reaped substantial benefits from government responses to the COVID-19 pandemic, especially those measures…

What’s on the Pharma Industry’s Radar for 2021?
By

By
COVID-19 will continue to be a defining issue for the pharmaceutical industry in 2021 as new vaccines and treatments enter the market. Across the broader industry, oncology drugs continue to…

The Biopharmaceutical Industry and Bioprocessing: What to Expect in 2021
By

By
The most important developments impacting the biopharma industry and bioprocessing in 2021 are COVID-19-related as vaccine and therapeutic development and biomanufacturing continue at a rapid pace. The pandemic is also…

The Path Behind Pfizer’s and BioNTech’s COVID-19 Vaccine
By

By
Having received emergency use authorization from the FDA for their COVID-19 vaccine, Pfizer and BioNTech reached a significant milestone in an unprecedented effort to develop a safe and effective vaccine…

CDMOs/CMOs: The Movers and Shakers of 2020
By

By
What were the key moves made by CDMOs/CMOs in 2020? Expansion activity was robust in biologic drug-substance and drug-product manufacturing, in part due to COVID-19-related projects, but other manufacturing segments…

Fine Chemicals: The EU Seeks To Fortify Supply Chains
By

By
Following the adoption of the European Commission’s Pharmaceutical Strategy for Europe late last month, EU policy makers are moving forward with ways to address vulnerabilities in the global drug supply…

Biomanufacturing Capacity and Supplies: COVID’s Impact
By

By
COVID-19 was the most important development impacting biomanufacturing in 2020. What have been, and what will be, the adjustments required of biopharma companies, CMOs, and suppliers to fortify production capacity…